What does this research mean for the field?

The prolyl isomerase Pin1 acts as a central regulator linking metabolic dysfunction to liver inflammation and fibrosis, making Pin1 inhibitors a promising therapeutic strategy for metabolic dysfunction-associated steatohepatitis (MASH). Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

Review the molecular mechanisms by which prolyl isomerase Pin1 regulates lipid metabolism and liver fibrosis to evaluate its potential as a therapeutic target for MASH.

September 3, 2026International Journal of Molecular SciencesOpen Access

Pin1 inhibitors may treat MASH by targeting metabolic-driven liver inflammation and fibrosis.

Q: What is the clinical evidence from this study?

Study design: Review. Population: Metabolic dysfunction-associated steatohepatitis (MASH). Intervention: Pin1.

View Full Paper

Ask AI

Bookmark

Why the study?

Do Pin1 inhibitors prevent the development of metabolic dysfunction-associated steatohepatitis (MASH)?

Population

Metabolic dysfunction-associated steatohepatitis models, including Pin1 conditional knockout mice on a…

Design

Review

Key result

The prolyl isomerase Pin1 acts as a central regulator linking metabolic dysfunction to liver inflammation and fibrosis, suggesting Pin1 inhibitors may be an effective treatment strategy for MASH.

Authors

YMYasuka Matsunaga MIM. Inoue MKMachi Kanna

Discussion

Member takes

Overview

Pin1 inhibition should not yet inform MASH care; extends preclinical evidence linking it to metabolic liver disease.

Key Points

Review the molecular mechanisms by which prolyl isomerase Pin1 regulates lipid metabolism and liver fibrosis to evaluate its potential as a therapeutic target for MASH.
Synthesized molecular and physiological evidence examining Pin1 function across liver and adipose tissues.
Assessed outcomes from preclinical animal models, including Pin1 conditional knockout mice fed high-calorie diets.
High-calorie diet upregulates Pin1, which suppresses fatty acid oxidation, thermogenesis, and lipolysis by modulating PPARα, PRDM16, and adipose triglyceride lipase.
Pin1 drives liver fibrosis by promoting the direct activation of hepatic stellate cells.
Pin1 conditional knockout mice demonstrate resistance to high-calorie diet-induced steatohepatitis and fibrotic progression.

Structured PICO

Do Pin1 inhibitors prevent the development of metabolic dysfunction-associated steatohepatitis (MASH)?

Population

Metabolic dysfunction-associated steatohepatitis (MASH) models, including Pin1 conditional knockout mice on a high-calorie diet

Exposure

Pin1 inhibitors

Outcome

MASH development, liver inflammation, and fibrosis

Pin1 acts as a central regulator linking metabolic dysfunction to liver inflammation and fibrosis, highlighting its potential as a therapeutic target for MASH.

Cite This Study

Matsunaga et al. (2026) conducted a review in Metabolic dysfunction-associated steatohepatitis (MASH). Pin1 was evaluated. The prolyl isomerase Pin1 acts as a central regulator linking metabolic dysfunction to liver inflammation and fibrosis, suggesting Pin1 inhibitors may be an effective treatment strategy for MASH.

synapsesocial.com/papers/6a993586636c6408cfa7dc69 https://doi.org/10.3390/ijms27177788

View Full Paper

Ask AI

Bookmark

September 3, 2026International Journal of Molecular SciencesOpen Access

Pin1 inhibitors may treat MASH by targeting metabolic-driven liver inflammation and fibrosis.

View Full Paper

Ask AI

Bookmark

Why the study?

Do Pin1 inhibitors prevent the development of metabolic dysfunction-associated steatohepatitis (MASH)?

Population

Metabolic dysfunction-associated steatohepatitis models, including Pin1 conditional knockout mice on a…

Design

Review

Key result

The prolyl isomerase Pin1 acts as a central regulator linking metabolic dysfunction to liver inflammation and fibrosis, suggesting Pin1 inhibitors may be an effective treatment strategy for MASH.

Authors

YMYasuka Matsunaga MIM. Inoue MKMachi Kanna

Discussion

Member takes

Overview

Pin1 inhibition should not yet inform MASH care; extends preclinical evidence linking it to metabolic liver disease.

Key Points

Review the molecular mechanisms by which prolyl isomerase Pin1 regulates lipid metabolism and liver fibrosis to evaluate its potential as a therapeutic target for MASH.
Synthesized molecular and physiological evidence examining Pin1 function across liver and adipose tissues.
Assessed outcomes from preclinical animal models, including Pin1 conditional knockout mice fed high-calorie diets.
High-calorie diet upregulates Pin1, which suppresses fatty acid oxidation, thermogenesis, and lipolysis by modulating PPARα, PRDM16, and adipose triglyceride lipase.
Pin1 drives liver fibrosis by promoting the direct activation of hepatic stellate cells.
Pin1 conditional knockout mice demonstrate resistance to high-calorie diet-induced steatohepatitis and fibrotic progression.

Structured PICO

Do Pin1 inhibitors prevent the development of metabolic dysfunction-associated steatohepatitis (MASH)?

Population

Metabolic dysfunction-associated steatohepatitis (MASH) models, including Pin1 conditional knockout mice on a high-calorie diet

Exposure

Pin1 inhibitors

Outcome

MASH development, liver inflammation, and fibrosis

Pin1 acts as a central regulator linking metabolic dysfunction to liver inflammation and fibrosis, highlighting its potential as a therapeutic target for MASH.

Cite This Study

synapsesocial.com/papers/6a993586636c6408cfa7dc69 https://doi.org/10.3390/ijms27177788

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark